Grace Therapeutics, Inc. (GRCE) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
103 Carnegie Center
Princeton, NJ 08540
United States of America (the)
Phone
818 839 4378
Website
Sector
Healthcare
Industry
Biotechnology
Employees
5
First IPO Date
February 07, 2012
| Name | Title | Pay | Year Born |
| Prashant Kohli | Chief Executive Officer & Director | 879,000 | 1972 |
| Carrie D'Andrea | Consultant | 413,500 | 1973 |
| Amresh Kumar | Vice President of Program Management | 413,500 | 1980 |
| Robert J. DelAversano | Vice President of Finance and Principal Financial & Accounting Officer | 0 | 1972 |
| R. Loch MacDonald | Member of Scientific Advisory Board & Chief Medical Officer | 0 | 1962 |
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.